Fibroblast Growth Factor Receptor Inhibitor–Associated Multifocal Serous Retinal Detachments: A Case Report

Abstract

Purpose: This report aims to describe a case of bilateral, multifocal neurosensory retinal detachments that developed during erdafitinib therapy for metastatic urothelial carcinoma. Methods: A case report with color fundus imaging and spectral-domain optical coherence tomography imaging is presented. Results: A 50-year-old man with metastatic urothelial carcinoma had an unremarkable baseline ophthalmic examination prior to starting erdafitinib. At 3-month follow up, an examination revealed bilateral, multifocal retinal detachments. Because the patient was asymptomatic and erdafitinib was the only drug to which his tumor had responded, he was kept on the medication with close ophthalmic monitoring. Conclusions: Erdafitinib, a fibroblast growth factor receptor inhibitor, can cause bilateral, multifocal retinal detachments. Continuation of erdafitinib may be considered in patients without significant visual impairment when the overall benefit of the medication appears to outweigh the risks.

Choroidal and Choriocapillaris Morphology in Pan-FGFR Inhibitor-Associated Retinopathy: A Case Report

“…Here we present a case of FGFR-associated retinopathy with a bilateral serous neuro-retinal detachment after erdafitinib. Similar clinical cases have previously been reported in the literature describing macular unifocal or multifocal serous neuroepithelial detachments [ 3 , 4 , 5 , 6 ]. To the best of our knowledge, this is the first case documented by choriocapillaris flow void evaluation with OCT-A.…”

“…Clinical features of FGFRAR also resemble previously described MEKAR in terms of patient symptoms, bilateralism, localization of foveal serous detachment, normal findings in FA and FAF examination [ 3 , 4 ]. The present normal ChT and stable choriocapillaris flow void fit a common mechanism.…”

Erdafitinib-induced bilateral multifocal serous retinal detachments and severe dry eye related unilateral peripheral ulcerative keratitis in a patient with metastatic urothelial carcinoma

“…Consequently, fluid accumulation between the neurosensory retina and RPE may occur and present with an appearance resembling central serous chorioretinopathy (CSC) [1] . Previous reports on erdafitinib-induced ocular complications were listed in Table 1 [1,[3][4][5][6][7][8][9][10][11][12][13][14][15] . During the phase II clinical studies of erdafitinib, Prensky et al [10] were the first to identify reversible macular lesions on OCT in two patients who presented with blurred vision.…”